Date and time
Start: Thursday 16 November 2023, 09:00 AM
End: Friday 17 November 2023, 01:00 PM
Thursday 16 November
Start: Thursday 16 November 2023, 09:00 AM
End: Friday 17 November 2023, 01:00 PM
The Grand Brighton, Grand Hotel, 97-99 Kings Road, Brighton, BN1 2FW
The CIPA Life Sciences Conference will take place on 16-17 November at The Grand Brighton, East Sussex.
The CIPA Life Sciences Conference is the UK’s premier annual educational and networking event for patent and IP professionals active in the pharma, medical technology and biotechnology sectors. The Conference has provided unrivalled expert insight into the latest developments in patents, regulatory and IP law in the global life science industry. Most importantly, the event provides a friendly environment for in-house and private practice professionals to network and share experiences.
The conference is now fully booked, if you would like to be added to the waiting list, please contact [email protected]
Wednesday Informal Dinner
The Conference will be preceded by an informal dinner on Wednesday evening in the Cyan Restaurant (Hotel’s Restaurant). Details on how to book will follow shortly.
COST:
Members
Full Conference (including seminar on both days, Thursday accommodation and dinner) – £600 + VAT
Wednesday Accommodation – £137.50 + VAT (B&B, single occupancy)
Thursday Seminar – £300.00 + VAT
Thursday Dinner – £100.00 + VAT
Thursday Accommodation – £137.50 + VAT (B&B, single occupancy)
Friday Seminar – £120.00 + VAT
Non- Members
Full Conference (including seminar on both days, Thursday accommodation and dinner) – £870 + VAT
Wednesday Accommodation – £137.50 + VAT (B&B, single occupancy)
Thursday Seminar – £400.00 + VAT
Thursday Dinner – £120.00 + VAT
Thursday Accommodation – £137.50 + VAT (B&B, single occupancy)
Friday Seminar – £180.00 + VAT
If you would like to sponsor any of our conferences, please check our sponsorship page for more information.
Members, Non Members
Provisional Programme, subject to change.
Simon has a Chemistry (with Biochemistry) degree from Bristol University and qualified as a UK patent attorney in 1990. He became a European Patent Attorney in 1992 while with Kilburn & Strode and joined J A Kemp in 1994. He became a partner in J A Kemp’s biotechnology group in 2005 and moved to Schlich on the south coast in January 2022.
Simon handles patent (and trade mark) work in a wide variety of life science, chemical and pharma fields, including stem cells, human genes and genomics, drug delivery systems, contrast agents, GM crops, algae technology and CRISPR technology. He also handles mechanical work ranging from drones to electric vehicle charging. He works for a broad variety of clients ranging from individuals, SMEs and private clients up to UK universities and biotechnology start-ups. He also acts for EU and US genomics and academic institutions.
Simon has chaired CIPA’s Life Sciences Committee for 20 years, and now also Chairs the epi Biotech committee and the UNION biotech committees. He is a member of CIPA’s Council, Patents Committee and International Liaison Committee. He is a member of epi Council and the By-Laws committee and has been selected to be a member of SACEPO. He enjoys wine, gigs, playing the sax, running and cycling.
Susan began working at GSK in 1998 as a patent trainee. Since then she’s worked in various IP roles across the company supporting small and large molecules, vaccines and technologies. Having spent the 2018 – 2022 leading the team that provides IP support to the Pharmaceutical portfolio, she moved teams at the beginning of 2023 to perform the same role for the Vaccines part of the business.
Dr Duncan Curley has over 25 years of experience of patent and trademark dispute resolution. He is a pharmaceutical specialist and acts for a number of companies (large and small) on freedom to operate, patent clearance and litigation issues.
He has worked on many high profile cases over the years, including Krka and Consilient Health v AstraZeneca (damages inquiry), Aspire Pharma v Allergan (bimatoprost formulation patent), Dr Reddy’s v Warner-Lambert (SPC paediatric extension challenge) and two of the major UK cases on antitrust ‘Eurodefences’ to IP claims (Sandvik v Pfiffner, patents and Sportswear v Stonestyle, trade marks).
He is a frequent author of articles on IP issues and his publications include the book “Intellectual Property Licences and Technology Transfer” (on the European Technology Transfer Block Exemption) and “Extending Rewards for Innovative Drug Development”, a Report on Supplementary Protection Certificates published by the Intellectual Property Institute.
Edward is a UK and European Patent Attorney focussed on software, natural language processing and AI. Before founding Added Matter, Edward spent almost a decade in private practice, including at Marks & Clerk.
Outside Added Matter, Edward codes in his spare time, and is an all-round AI evangelist.
Edward has a degree in physics.
Richard has over 20 years’ experience litigating before the English Patent Court as well as oppositions and appeals before the EPO and is equally familiar with both jurisdictions.
Before commencing practice at the Bar, Richard qualified as a European Patent Attorney and this dual qualification has resulted in him appearing frequently before the European Patent Office and giving him representation rights before the UPC.
Richard’s practice encompasses a diverse range of technologies. He has particular expertise in the electronics / telecommunications sector having advised many of the major players in the field such as LG Electronics, Samsung, Nokia, Motorola and Symbian. Although by training an electrical engineer, he is active in the pharmaceutical sector and acted for the Secretary of State for Health in the ground breaking second medical indication litigation concerning pregabalin.
Richard lectures and tutors regularly on IPRs to patent and trade mark attorneys and solicitors. He has tutored at Nottingham Law School on its LLM in Advanced IP litigation and been a visiting lecturer of CEIPI on the European patent litigation diploma. Richard is now one of the two General Editors of the CIPA Guide to the Patents Acts (the Black Book).
It was recently announced that he will be appointed King’s Counsel (silk) in early 2023.
Andrea is a Chartered Patent Attorney and a former CIPA President. In the past she has served on the Institute’s governing Council and several of its committees.
Before her retirement she was a partner in a small regional IP practice, Greaves Brewster LLP, of which she had been a co-founder.
Andrea established IP Inclusive in 2015 to promote equality, diversity, inclusion (EDI) and wellbeing throughout the UK’s IP professions. Alongside many enthusiastic volunteers, she has developed the initiative into a well-connected and influential player in the IP sector. She became its first Lead Executive Officer in 2019.
Nicole is a life sciences partner at Pinsent Masons. She has a stellar reputation for resolving IP disputes and providing strategic IP and regulatory advice to a wide range of clients in the life science sector, from global pharmaceutical companies to small biotechs, and frequently advises and co-ordinates advice and litigation on a multi-jurisdictional basis.
With a science degree and first-hand experience of the life sciences industry (including working for a global pharmaceutical company in clinical trials before qualifying as lawyer), she is well placed to understand and advise on issues relevant to the sector. She is immersed in such issues as Vice Chair of the IP committee of the BioIndustry Association and as a member of CIPA’s life sciences committee.
Julyan Elbro is Divisional Director in charge of Patent Examination in the Intellectual Property Office, with overall responsibility for the patents service. . With an academic background in mathematics and computer science, he has worked at the Intellectual Property Office since 1998, originally as a Patent Examiner, but also spending some time in the Office’s Policy Directorate covering a range of portfolios including biotechnology, pharmaceuticals, and the World Trade Organisation TRIPs Agreement. He returned to patent examining in 2006 as head of the group dealing with computing inventions, before moving to his current position in June 2009.
Dr Lawrence Cullen was a Deputy Director at the Intellectual Property Office (IPO) in the UK from 2007 to 2024 where he had responsibility for operational delivery of Supplementary Protection Certificates (SPCs). He has recently left this role to establish his own consultancy and to develop his interests further in the role and relevance of SPCs. Dr Cullen joined the IPO in 1997 as a patent examiner in the chemistry field and worked in a variety of operational, technical and policy roles in patents and trademarks before taking on the Deputy Director role. He has extensive experience working in the area of pharma and biotech patents as well as SPCs. Dr Cullen has a wide experience as a hearing officer dealing with questions of validity. He has been directly involved in over 50 patent and over 25 SPC cases before the IPO, the UK courts and, prior to 2021, the Court of Justice of the European Union (CJEU). He has also worked as a hearing officer dealing with trade-mark disputes. Dr Cullen was educated in chemistry in Ireland and the UK and worked as a research
scientist at various universities in Europe and USA before joining the IPO.
Nicole is a life sciences partner at Pinsent Masons. She has a stellar reputation for resolving IP disputes and providing strategic IP and regulatory advice to a wide range of clients in the life science sector, from global pharmaceutical companies to small biotechs, and frequently advises and co-ordinates advice and litigation on a multi-jurisdictional basis.
With a science degree and first-hand experience of the life sciences industry (including working for a global pharmaceutical company in clinical trials before qualifying as lawyer), she is well placed to understand and advise on issues relevant to the sector. She is immersed in such issues as Vice Chair of the IP committee of the BioIndustry Association and as a member of CIPA’s life sciences committee.
Dr Lawrence Cullen was a Deputy Director at the Intellectual Property Office (IPO) in the UK from 2007 to 2024 where he had responsibility for operational delivery of Supplementary Protection Certificates (SPCs). He has recently left this role to establish his own consultancy and to develop his interests further in the role and relevance of SPCs. Dr Cullen joined the IPO in 1997 as a patent examiner in the chemistry field and worked in a variety of operational, technical and policy roles in patents and trademarks before taking on the Deputy Director role. He has extensive experience working in the area of pharma and biotech patents as well as SPCs. Dr Cullen has a wide experience as a hearing officer dealing with questions of validity. He has been directly involved in over 50 patent and over 25 SPC cases before the IPO, the UK courts and, prior to 2021, the Court of Justice of the European Union (CJEU). He has also worked as a hearing officer dealing with trade-mark disputes. Dr Cullen was educated in chemistry in Ireland and the UK and worked as a research
scientist at various universities in Europe and USA before joining the IPO.
Julyan Elbro is Divisional Director in charge of Patent Examination in the Intellectual Property Office, with overall responsibility for the patents service. . With an academic background in mathematics and computer science, he has worked at the Intellectual Property Office since 1998, originally as a Patent Examiner, but also spending some time in the Office’s Policy Directorate covering a range of portfolios including biotechnology, pharmaceuticals, and the World Trade Organisation TRIPs Agreement. He returned to patent examining in 2006 as head of the group dealing with computing inventions, before moving to his current position in June 2009.
Sign in to your account to register for the event
If you are not yet registered or a member of CIPA, please register here